Literature DB >> 10937104

Midline cleft. Treatment of the bifid nose.

P J Miller1, D Grinberg, T D Wang.   

Abstract

BACKGROUND: Midline facial clefts are rare deformities with a wide range of clinical findings from a simple midline vermillion notch to major skeletal malformations, including orbital hypertelorism. The bifid nose is a relatively uncommon malformation that is frequently associated with hypertelorbitism and midline clefts of the lip. The presentation of a bifid nose ranges from a minimally noticeable midline nasal tip central groove to a complete clefting of the osteocartilaginous framework, resulting in 2 complete half noses. We describe our experience with 2 patients with midface clefts who presented with bifid noses and a variety of other congenital abnormalities. The anatomy, extensive treatment, and complications of the bifid nose are discussed.
DESIGN: Retrospective case review and literature review.
RESULTS: Successful creation of an aesthetic nasal contour and normal nasal function was achieved without complication via extensive skin, bony, and cartilaginous resection.
CONCLUSIONS: The bifid nose challenges the rhinoplasty surgeon. A successful outcome is dependent on a thorough understanding of the bifid nasal anatomy, proper patient evaluation, careful preoperative planning, and meticulous surgical technique.

Entities:  

Mesh:

Year:  1999        PMID: 10937104     DOI: 10.1001/archfaci.1.3.200

Source DB:  PubMed          Journal:  Arch Facial Plast Surg        ISSN: 1521-2491


  3 in total

Review 1.  Diagnostic imaging features of congenital nose and nasal cavity lesions.

Authors:  D T Ginat; C D Robson
Journal:  Clin Neuroradiol       Date:  2014-08-06       Impact factor: 3.649

Review 2.  CT and MRI of congenital nasal lesions in syndromic conditions.

Authors:  Daniel T Ginat; Caroline D Robson
Journal:  Pediatr Radiol       Date:  2015-01-09

Review 3.  Classification of congenital nasal deformities: a proposal to amend the existing classification.

Authors:  Marta Fijałkowska; Bogusław Antoszewski
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-07-06       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.